Search results

Skip to results

Type

Status

Last updated

Showing 61 to 75 of 101 results for melanoma

  1. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued Reference number: GID-TA10686

  2. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

  3. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

  4. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

  5. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074

  6. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued Reference number: GID-TA10354

  7. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued Reference number: GID-TA10213

  8. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

  9. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

  10. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued Reference number: GID-TA10543

  11. Medical technologies guidance - static list

    We regularly review our medical technologies guidance, and if there is no new research or evidence available that would have a material effect, it gets moved to the static list.

  12. Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment (HTE24)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin...

  13. Endoscopic radical inguinal lymphadenectomy (IPG398)

    Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.

  14. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.